|
1
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69(Suppl 3): 4–10. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar
|
|
3
|
Ferrara N, Gerber HP and Le Couter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrara N: Role of vascular endothelial
growth factor in regulation of physiological angiogenesis. Am J
Physiol Cell Physiol. 280:C1358–C1366. 2001.PubMed/NCBI
|
|
5
|
Ferrara N: Vascular endothelial growth
factor as target for anticancer therapy. Oncologist. 9(Suppl 1):
2–10. 2004. View Article : Google Scholar
|
|
6
|
Shweiki D, Itin A, Soffer D and Kesdet E:
Vascular endothelial growth factor induced by hypoxia may mediate
hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Popovici C, Roubin R, Coulier F and
Birnbaum D: An evolutionary history of the FGF superfamily.
Bioessays. 27:849–857. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bottcher RT and Niehrs C: Fibroblast
growth factor signaling during vertebrate development. Endocr Rev.
26:63–77. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Powers CJ, McLeskey SW and Wellstein A:
Fibroblast growth factors, their receptors and signaling. Endocr
Rel Cancer. 7:165–197. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayes DF: Prognostic and predictive
factors revisited. Breast. 14:493–499. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1010–1027. 2005.PubMed/NCBI
|
|
12
|
Larsson A, Sköldenberg E and Ericson H:
Serum and plasma levels of FGF-2 and VEGF in healthy blood donors.
Angiogenesis. 5:107–110. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Potgens A, Westphal H, De Waal R and
Ruiter D: The role of vascular permeability factor and basic
fibroblast growth factor in tumor angiogenesis. Biol Chem
Hoppe-Seyler. 376:57–70. 1995.PubMed/NCBI
|
|
14
|
Relf M, LeJeune S, Scott PA, et al:
Expression of the angiogenic factors vascular endothelial cell
growth factor, acidic and basic fibroblast growth factor, tumor
growth factor beta-1, platelet-derived endothelial cell growth
factor, placenta growth factor, and pleiothophin in human primary
breast cancer and its relation to angiogenesis. Cancer Res.
57:963–969. 1997.
|
|
15
|
Agnantis NJ, Goussia AC, Batistatou A and
Stefanou D: Tumor markers in cancer patients: an update of their
prognostic significance (part II). In Vivo. 18:481–485.
2004.PubMed/NCBI
|
|
16
|
Gasparini G: Clinical significance of
determination of surrogate markers of angiogenesis in breast
cancer. Crit Rev Oncol Hematol. 37:97–114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eppenberger U, Kueng W, Schlaeppi JM, et
al: Markers of tumor angiogenesis and protelysis independently
define high- and low-risk subsets of node negative breast cancer
patients. J Clin Oncol. 16:3129–3136. 1998.PubMed/NCBI
|
|
18
|
Smith K, Fox SB, Whitehouse R, et al:
Upregulation of bFGF in breast carcinoma and its relationship to
vascular density, estrogen receptor, epidermal growth factor
receptor and survival. Ann Oncol. 10:707–713. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yiangon C, Gomm JJ, Coope RC, et al:
Fibroblast growth factor 2 in breast cancer: occurrence and
prognostic significance. Br J Cancer. 75:28–33. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Colomer R, Aparicio J, Montero S, Guzman
C, Larrodera L and Cortes-Funes H: Low levels of bFGF are
associated with poor prognosis in human breast carcinoma. Br J
Cancer. 76:1215–1220. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Giantonio BJ, Katalano PJ, Meropol NJ, et
al: Bevacizumab in combination with oxaliplatin, fluorouracil and
leucovorin (FOLFOX4) for previously treated metastatic colorectal
cancer: results from the Eastern Cooperative Oncology Group Study E
3200. J Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar
|
|
22
|
Saltz LA, Clarke S, Diaz-Rubio E, et al:
Bevacizumab in combination with oxaliplatin-based chemotherapy as
first-line therapy in metastatic colorectal cancer: a randomized
phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69(Suppl 3): 4–10. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ellis LM and Haller DG: Bevacizumab beyond
progression: Does this make sense? Editorial J Clin Oncol. 3:1–3.
2009.
|
